QCM
BCAX

Quantinno Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Quantinno Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.9M Buy
63,978
+46,366
+263% +$1.03M ﹤0.01% 2013
2026
Q1 		$350K Buy
17,612
+2,447
+16% +$42.1K ﹤0.01% 2944
2025
Q4 		$255K Buy
15,165
+4,588
+43% +$78.4K ﹤0.01% 2930
2025
Q3 		$167K Buy
+10,577
New +$118K ﹤0.01% 2808

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Quantinno Capital Management's BCAX Position: Q2 2026 in Review

Quantinno Capital Management increased its Bicara Therapeutics (BCAX) stake by 263% in Q2 2026, buying an estimated $1.03M and bringing the position to 63,978 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2013.

Quantinno Capital Management first reported a position in BCAX in Q3 2025 and has held it in 4 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Quantinno Capital Management held 63,978 shares of Bicara Therapeutics worth $1.9M as of Q2 2026.
  • Quantinno Capital Management bought 46,366 Bicara Therapeutics shares in Q2 2026, an estimated $1.03M.
  • Bicara Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2013 holding.
  • Quantinno Capital Management first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.